Featured Research

from universities, journals, and other organizations

HIV-1 Protease Inhibitor Induced Oxidative Stress In Pancreatic B-cells: Thymoquinone Protection

Date:
March 25, 2009
Source:
Society for Experimental Biology and Medicine
Summary:
Researchers have discovered that the HIV-1 protease inhibitors, such as nelfinavir included in highly active antiretroviral therapy regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway. They report a significant decrease in the levels of the antioxidants, cytosolic superoxide dismutase and glutathione, whereas mitochondrial SOD levels remained unaffected in pancreatic beta-cells exposed to nelfinavir.

Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway.

They report a significant decrease in the levels of the antioxidants, cytosolic superoxide dismutase (Cu/Zn SOD) and glutathione, whereas mitochondrial SOD levels remained unaffected in pancreatic beta-cells (INS-1 cells) exposed to nelfinavir. However, the mitochondrial uncoupling protein (UCP2) levels were up-regulated during nelfinavir induced oxidative stress and directly affected the ATP levels in these cells. A significant decrease in ATP production was also observed which may account for the decrease in glucose stimulated insulin secretion upon nelfinavir treatment.

This study appears in the April 2009 issue of Experimental Biology and Medicine.

Although insulin resistance has been clinically observed in HIV-1 patients receiving HAART regimen, the molecular mechanisms of this metabolic abnormality have not been delineated.

The research team led by Dr. Krishna C. Agrawal, Regents Professor and Chairman included Surabhi Chandra, a graduate student and another faculty member, Dr. Debasis Mondal in the Department of Pharmacology. These investigators successfully tested the hypothesis that nelfinavir induced oxidative stress was responsible for the deleterious effects of the HIV-1 protease inhibitor on insulin production by pancreatic beta-cells and they further investigated the therapeutic strategies to ameliorate the insulin dysregulation at this level. Since the hypoglycemic effects of Nigella sativa oil have been investigated in the past, the investigators postulated that nelfinavir induced oxidative stress may be ameliorated by the administration of the active ingredient of this oil, thymoquinone.

Furthermore, it was envisioned that since thymoquinone shares a structural homology with ubiquinone (mitochondrial component) it is likely that it may act as a mitochondrial antioxidant. Indeed pretreatment of pancreatic beta-cells with thymoquinone caused a reversal of nelfinavir induced deleterious effects. Thymoquinone decreased the production of reactive oxygen species, increased the Cu/Zn SOD and glutathione levels, suppressed the UCP-2 protein levels and restored nelfinavir induced decrease in insulin secretion to normal levels in these cells.

Dr. Agrawal commented, "An important finding of this study is that the dysregulation of insulin production in pancreatic beta-cells is due to generation of reactive oxygen species induced by nelfinavir, an HIV-1 protease inhibitor."

Furthermore, Dr. Agrawal said, "thymoquinone, an antioxidant provided a significant protection to pancreatic beta-cells from the toxic effects of nelfinavir and therefore these findings clearly suggest a potential role for the use of black seed oil or thymoquione as a protective agent against HIV-1 protease inhibitor induced deleterious effects on pancreatic beta-cells."


Story Source:

The above story is based on materials provided by Society for Experimental Biology and Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Experimental Biology and Medicine. "HIV-1 Protease Inhibitor Induced Oxidative Stress In Pancreatic B-cells: Thymoquinone Protection." ScienceDaily. ScienceDaily, 25 March 2009. <www.sciencedaily.com/releases/2009/03/090325132502.htm>.
Society for Experimental Biology and Medicine. (2009, March 25). HIV-1 Protease Inhibitor Induced Oxidative Stress In Pancreatic B-cells: Thymoquinone Protection. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/03/090325132502.htm
Society for Experimental Biology and Medicine. "HIV-1 Protease Inhibitor Induced Oxidative Stress In Pancreatic B-cells: Thymoquinone Protection." ScienceDaily. www.sciencedaily.com/releases/2009/03/090325132502.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins